EUVIMEDEUVIMED entdecken
Crossref

Effect of Cholecalciferol Supplementation on CVD, Inflammation, and Bone Metabolism Markers in CKD: A Randomized Double Blind Placebo Controlled Feasibility Trial

Kajal Kamboj, Karthikeyan Manoharan, Shubham Sharma, Himanshi Khera, Nusrat Shafiq, Harbir Singh Kohli, Ashok Kumar Yadav, Vivek Kumar, Vivekanand Jha

Indian Journal of Nephrology · 12.06.2026 · 1-9

DOI: 10.25259/ijn_110_2026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Nephrology, online erschienen am 12.06.2026. Verfasst von Kajal Kamboj und 8 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vitamin D deficiency is common in CKD and associated with cardiovascular disease (CVD) and bone mineral metabolism. The long-term impact of cholecalciferol supplementation on CVD is unknown. We tested the effects of cholecalciferol supplementation on CVD outcomes [major adverse cardiovascular events (MACE)], progression of CKD, and markers of bone mineral metabolism and inflammation in patients with pre-dialysis CKD. Materials and Methods The study was a single-center, prospective, randomized, placebo-controlled, double blind clinical trial. Patients with CKD, between 18-75 years, estimated glomerular filtration rate 10-45 mL/min/1.73m 2 , serum 25(OH)D levels 20-50 ng/mL were enrolled. Participants received either cholecalciferol 60000 IU once/2 weeks or a matching placebo and followed up at every 3 months till 36 months after enrolment. All clinical, demographic, and biomarker characteristics were analyzed at baseline and at annual follow-up.

Results

692 participants were screened, of which 126 were enrolled. However, 37 participants dropped before randomization. 89 participants were randomized: 46 to the cholecalciferol group and 43 to the placebo group. Both groups were similar with respect to MACE events, need for renal replacement therapy, and all-cause mortality. Over one year, serum 25(OH)D increased in the cholecalciferol group [Mean diff between groups: 31.89, 95% CI: 20.46 to 43.32, p

Zitieren

APA

Kamboj, K., Manoharan, K., Sharma, S., Khera, H., Shafiq, N., Kohli, H. S., Yadav, A. K., Kumar, V., & Jha, V. (2026). Effect of Cholecalciferol Supplementation on CVD, Inflammation, and Bone Metabolism Markers in CKD: A Randomized Double Blind Placebo Controlled Feasibility Trial. Indian Journal of Nephrology, 0, 1-9. https://doi.org/10.25259/ijn_110_2026

Vancouver

Kamboj K, Manoharan K, Sharma S, Khera H, Shafiq N, Kohli HS, et al. Effect of Cholecalciferol Supplementation on CVD, Inflammation, and Bone Metabolism Markers in CKD: A Randomized Double Blind Placebo Controlled Feasibility Trial. Indian Journal of Nephrology. 2026;0:1-9. doi:10.25259/ijn_110_2026

BibTeX
@article{Kamboj2026,
  author = {Kamboj, Kajal and Manoharan, Karthikeyan and Sharma, Shubham and Khera, Himanshi and Shafiq, Nusrat and Kohli, Harbir Singh and Yadav, Ashok Kumar and Kumar, Vivek and Jha, Vivekanand},
  title = {Effect of Cholecalciferol Supplementation on CVD, Inflammation, and Bone Metabolism Markers in CKD: A Randomized Double Blind Placebo Controlled Feasibility Trial},
  journal = {Indian Journal of Nephrology},
  year = {2026},
  volume = {0},
  pages = {1--9},
  doi = {10.25259/ijn_110_2026}
}
Kostenlos starten →